<code id='A2A63C2AFA'></code><style id='A2A63C2AFA'></style>
    • <acronym id='A2A63C2AFA'></acronym>
      <center id='A2A63C2AFA'><center id='A2A63C2AFA'><tfoot id='A2A63C2AFA'></tfoot></center><abbr id='A2A63C2AFA'><dir id='A2A63C2AFA'><tfoot id='A2A63C2AFA'></tfoot><noframes id='A2A63C2AFA'>

    • <optgroup id='A2A63C2AFA'><strike id='A2A63C2AFA'><sup id='A2A63C2AFA'></sup></strike><code id='A2A63C2AFA'></code></optgroup>
        1. <b id='A2A63C2AFA'><label id='A2A63C2AFA'><select id='A2A63C2AFA'><dt id='A2A63C2AFA'><span id='A2A63C2AFA'></span></dt></select></label></b><u id='A2A63C2AFA'></u>
          <i id='A2A63C2AFA'><strike id='A2A63C2AFA'><tt id='A2A63C2AFA'><pre id='A2A63C2AFA'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          focus

          author:knowledge    - browse:832
          Alastair Grant/AP

          LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

          The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

          advertisement

          AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus